Document is current
Any future updates will be listed below
-
Authors
Strati, Paolo https://orcid.org/0000-0002-7445-1459
Feng, Lei
Westin, Jason R. https://orcid.org/0000-0002-1824-2337
Nair, Ranjit
Fayad, Luis E.
Rodriguez, Maria A. https://orcid.org/0000-0002-3564-8697
Chihara, Dai
Malpica, Luis
Henderson, Jared https://orcid.org/0000-0002-5121-5234
Gallardo, Mariana
Rivera, Marissa
Wang, Iris
Bolshakova, Anastasiia
Radko, Anastasia
Kurtz, David https://orcid.org/0000-0002-6382-4651
Alig, Stefan K. https://orcid.org/0000-0001-6825-702X
Flowers, Christopher R.
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
Neelapu, Sattva S. https://orcid.org/0000-0003-1045-4914
-
Funding
Funding for this research was provided by:
Gilead Foundation (CDA)
Andrew Sabin Family Foundation (CDA)
AstraZeneca (Clinical trial support)
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 22 July 2025
First Online: 7 August 2025
Competing interests
: P.S. is a consultant for Roche-Genentech, Abbvie-Genmab, Ipsen, Kite/Gilead, Hutchison MediPharma, AstraZeneca-Acerta, ADC Therapeutics, Sobi, and TG Therapeutics; he has received research funds from Sobi, AstraZeneca-Acerta, ALX Oncology, and ADC Therapeutics. S.S.N. received research support from Kite/Gilead, BMS, Allogene, Precision Biosciences, Adicet Bio, and Sana Biotechnology; served as Advisory Board Member/Consultant for Kite/Gilead, Merck, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, Morphosys, Janssen, Chimagen, ImmunoACT, Orna Therapeutics, Takeda, and Synthekine; has stock options from Longbow Immunotherapy, Inc; and has intellectual property related to cell therapy. S.K.A. reports consultancy for Foresight Diagnostics. The remaining authors declare no competing interests.
